Identification of Independent Primary Tumors and Intrapulmonary Metastases Using DNA Rearrangements in Non–Small-Cell Lung Cancer

Abstract

Purpose Distinguishing independent primary tumors from intrapulmonary metastases in non–small-cell carcinoma remains a clinical dilemma with significant clinical implications. Using next-generation DNA sequencing, we developed a chromosomal rearrangement–based approach to differentiate multiple primary tumors from metastasis. Methods Tumor specimens from patients with known independent primary tumors and metastatic lesions were used for lineage test development, which was then applied to multifocal tumors. Laser capture microdissection was performed separately for each tumor. Genomic DNA was isolated using direct in situ whole-genome amplification methodology, and next-generation sequencing was performed using an Illumina mate-pair library protocol. Sequence reads were mapped to the human genome, and primers spanning the fusion junctions were used for validation polymerase chain reaction. Results A total of 41 tumor samples were sequenced (33 adenocarcinomas [ADs] and eight squamous cell carcinomas [SQCCs]), with a range of three to 276 breakpoints per tumor identified. Lung tumors predicted to be independent primary tumors based on different histologic subtype did not share any genomic rearrangements. In patients with lung primary tumors and paired distant metastases, shared rearrangements were identified in all tumor pairs, emphasizing the patient specificity of identified breakpoints. Multifocal AD and SQCC samples were reviewed independently by two pulmonary pathologists. Concordance between histology and genomic data occurred in the majority of samples. Discrepant tumor samples were resolved by genome sequencing. Conclusion A diagnostic lineage test based on genomic rearrangements from mate-pair sequencing demonstrates promise for distinguishing independent primary from metastatic disease in lung cancer.

Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging

“…Recent more comprehensive approaches also reported inconclusive results. 31 Murphy et al 31 proposed that the assessment of DNA rearrangements by next-generation DNA sequencing might be a better approach as identifier of lineage than single-nucleotide mutations, but unfortunately no survival data were provided to support the merit of this suggestion. At this time, use of next-generation sequencing in the detection of gene rearrangements is limited, complex and more suitable as a research tool.…”

A case of different EGFR mutations in surgically resected synchronous triple lung cancer

“…Although the criteria are based on tumor locations and histological findings, in clinical practice, some cases, such as those with multifocal GGNs, do not meet the criteria. In recent years, great advances have been made in distinguishing multifocal lung cancer using gene profile analyses, such as comparative genomic hybridization or next-generation sequencing (8,9); however, there is no gold-standard method, and the available methods are too complex to feasibly integrate into routine clinical practice. We therefore adhered to the clinical and pathological criteria of the IASLC Lung Cancer Staging Project (2).…”

Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma

“…19,20 SVAtools is an in-house R package, developed by the Biomarker Discovery Lab at Mayo Clinic. Briefly, all read-pairs are sorted by mapped chromosome and position for rapid indexing.…”